Polyrizon Ltd. Secures $17M to Propel Its Revolutionary Nasal Hydrogel Biological Mask Innovation

Polyrizon Ltd., a forward-thinking development-stage biotech company, is excited to announce that it has successfully raised 17,000,000 in funding. This significant milestone marks a pivotal step forward in the company’s mission to reimagine protection against airborne pathogens and allergens. Specializing in innovative medical device hydrogels, Polyrizon leverages its proprietary Capture and Contain™ (C&C) technology to develop nasal sprays that form a thin, hydrogel-based shield within the nasal cavity. This unique “biological mask” is designed to provide a physical barrier, preventing viruses and allergens from making contact with the delicate nasal epithelial tissue. With this infusion of capital, Polyrizon aims to accelerate the development and optimization of its C&C hydrogel formulation, particularly focusing on enhancing bioadhesion and prolonged retention at the nasal deposition site. These improvements are critical for the effective intranasal delivery of both protective agents and therapeutic drugs. Moreover, the latest funding round will support the further research and pre-clinical development of the company’s secondary innovation, Trap and Target™ (T&T), which is dedicated to the nasal delivery of active pharmaceutical ingredients (APIs). By broadening the potential applications of their groundbreaking technologies, Polyrizon is positioning itself at the forefront of a new wave of non-invasive medical interventions. The raised funds will not only bolster research and development efforts but also facilitate strategic collaborations, paving the way for future clinical trials and, ultimately, market-ready solutions in the fight against respiratory hazards.